| 1 |
35194103 | CYP2B6 allelic variants and non-genetic factors influence CYP2B6 enzyme function. | 2022 Feb 22 |
1 |
| 2 |
35579950 | Targeting CAR and Nrf2 improves cyclophosphamide bioactivation while reducing doxorubicin-induced cardiotoxicity in triple-negative breast cancer treatment. | 2022 Jun 22 |
2 |
| 3 |
35606478 | Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer. | 2022 May 24 |
1 |
| 4 |
33599403 | Allelic and genotype frequencies of major CYP2B6 polymorphisms in the Pakistani population. | 2021 Mar |
1 |
| 5 |
33872945 | Identification of miRNAs that regulate human CYP2B6 expression. | 2021 Jun |
2 |
| 6 |
33992954 | Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6. | 2021 Aug |
2 |
| 7 |
34746455 | The correlation between the level of 3-hydroxypropyl mercapturic acid, CYP2B6 polymorphisms, and hematuria occurrences after cyclophosphamide administration and its bioanalytical methods: A systematic review. | 2021 Oct |
10 |
| 8 |
30778771 | Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients. | 2020 Apr |
1 |
| 9 |
33233444 | CITCO as an Adjuvant Facilitates CHOP-Based Lymphoma Treatment in hCAR-Transgenic Mice. | 2020 Nov 21 |
1 |
| 10 |
30320358 | Hypoxia increases chemoresistance in human medulloblastoma DAOY cells via hypoxia‑inducible factor 1α‑mediated downregulation of the CYP2B6, CYP3A4 and CYP3A5 enzymes and inhibition of cell proliferation. | 2019 Jan |
1 |
| 11 |
31218720 | The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes. | 2019 Sep |
1 |
| 12 |
31247375 | Human constitutive androstane receptor agonist DL5016: A novel sensitizer for cyclophosphamide-based chemotherapies. | 2019 Oct 1 |
2 |
| 13 |
31686598 | Severe and prolonged cyclophosphamide-induced hepatotoxicity in a breast cancer patient carrying a CYP2B6*7 variant. | 2019 Nov |
2 |
| 14 |
29914177 | Effect of Nicotine on CYP2B1 Expression in a Glioma Animal Model and Analysis of CYP2B6 Expression in Pediatric Gliomas. | 2018 Jun 16 |
1 |
| 15 |
30201214 | Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation. | 2018 Oct |
2 |
| 16 |
29081796 | Hepatocyte CYP2B6 Can Be Expressed in Cell Culture Systems by Exerting Physiological Levels of Shear: Implications for ADME Testing. | 2017 |
1 |
| 17 |
26456622 | Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus. | 2016 Feb |
1 |
| 18 |
26823489 | Activation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma Treatment. | 2016 Mar |
2 |
| 19 |
27388155 | CYP2B6rs2279343 Is Associated with Improved Survival of Pediatric Rhabdomyosarcoma Treated with Cyclophosphamide. | 2016 |
4 |
| 20 |
27709010 | Insights into CYP2B6-mediated drug-drug interactions. | 2016 Sep |
1 |
| 21 |
25428516 | Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer. | 2015 Jan |
2 |
| 22 |
25601761 | Cytochrome P450 2J2, a new key enzyme in cyclophosphamide bioactivation and a potential biomarker for hematological malignancies. | 2015 Oct |
1 |
| 23 |
25677220 | Cytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for Lymphoma. | 2015 May |
3 |
| 24 |
25860621 | Prediction of Drug-Induced Liver Injury in HepG2 Cells Cultured with Human Liver Microsomes. | 2015 May 18 |
1 |
| 25 |
26544874 | Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation. | 2015 |
5 |
| 26 |
26681005 | Prevalence of CYP2B6 polymorphisms in Argentinians: the role of genetic testing. | 2015 Dec 11 |
1 |
| 27 |
24548980 | A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis. | 2014 Apr |
1 |
| 28 |
24768782 | Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy. | 2014 Jul 1 |
1 |
| 29 |
23160467 | The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies. | 2013 Jan 10 |
3 |
| 30 |
23467454 | Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. | 2013 |
1 |
| 31 |
24128861 | CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. | 2013 Dec 19 |
2 |
| 32 |
21741706 | Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients. | 2012 Jan |
2 |
| 33 |
21976622 | Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo. | 2012 Jan |
3 |
| 34 |
22159699 | Which CYP2B6 variants have functional consequences for cyclophosphamide bioactivation? | 2012 Mar |
1 |
| 35 |
22245954 | The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. | 2012 May |
1 |
| 36 |
22380717 | Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. | 2012 Sep |
2 |
| 37 |
21165551 | Genetically modified macrophages expressing hypoxia regulated cytochrome P450 and P450 reductase for the treatment of cancer. | 2011 Feb |
4 |
| 38 |
21442647 | The importance of correct assignment of CYP2B6 genetic variants with respect to cyclophosphamide metabolizer status. | 2011 Apr |
1 |
| 39 |
21487929 | The role of constitutive androstane receptor in oxazaphosphorine-mediated induction of drug-metabolizing enzymes in human hepatocytes. | 2011 Aug |
4 |
| 40 |
21543025 | Cytochrome P450 polymorphisms and the response of lupus nephritis to cyclophosphamide therapy. | 2011 May |
1 |
| 41 |
21821736 | Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262. | 2011 Nov |
3 |
| 42 |
19653275 | Primary gene-engineered neural stem/progenitor cells demonstrate tumor-selective migration and antitumor effects in glioma. | 2010 Mar 1 |
4 |
| 43 |
20836875 | Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+. | 2010 Sep 13 |
4 |
| 44 |
21108329 | Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. | 2010 Dec |
1 |
| 45 |
21175440 | The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. | 2010 Dec |
3 |
| 46 |
19005482 | Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. | 2009 Mar |
4 |
| 47 |
19702527 | Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. | 2009 Sep |
1 |
| 48 |
17875191 | Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms. | 2008 Feb |
1 |
| 49 |
18171905 | Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. | 2008 Apr |
1 |
| 50 |
18212249 | Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo. | 2008 Apr |
10 |